Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Breast Neoplasms 14Endometrial Neoplasms 11Ovarian Neoplasms 10Pancreatic Neoplasms 9Stomach Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Uterine Cervical Neoplasms 6Prostatic Neoplasms 6Colorectal Neoplasms 6Urinary Bladder Neoplasms 5Lung Neoplasms 5Esophageal Neoplasms 5Neoplasms 4Breast Neoplasms, Male 4Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Neoplasm Metastasis 3Gallbladder Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Hepatocellular 3Vulvar Neoplasms 2Vipoma 2Vaginal Neoplasms 2Uterine Neoplasms 2Urethral Neoplasms 2

Interventions

Paclitaxel 13pembrolizumab 8Carboplatin 7Surveys and Questionnaires 6Cisplatin 6Brachytherapy 5Doxorubicin 4Docetaxel 4Pemetrexed 3Hyperthermic Intraperitoneal Chemotherapy 3Gemcitabine 3FANG vaccine 3Biopsy 3osimertinib 2olaparib 2niraparib 2durvalumab 2adavosertib 2Trastuzumab 2Topotecan 2Taxes 2Standard of Care 2Sentinel Lymph Node Biopsy 2Saline Solution 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Oxaliplatin 2Nivolumab 2Music Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Neoplasms × Trastuzumab × Gynecologic × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡